Partner Headlines - NPSP

  1. Benzinga's Weekend M&A Chatter

    Benzinga
  2. Technology Stocks Down As Rest Of The Market Starts Week Flat

    Benzinga
  3. Terex Falls After Lowered Earnings Forecast; Avanir Pharmaceuticals ...

    Benzinga
  4. NASDAQ Tumbles 1.1%; Alere Shares Surge Following Proposed $46/Share ...

    Benzinga
  5. Markets Fall; Cognizant To Acquire TriZetto For $2.7 Billion

    Benzinga
  6. Morning Market Losers

    Benzinga
  7. Benzinga's Top #PreMarket Losers

    Benzinga
  8. US Stock Futures Flat Ahead Of Economic Data

    Benzinga
  9. NPS Pharma Stock Trading Halted Today; FDA Advisory Committee ...

    Benzinga
  10. FDA says NPS drug is effective

    IBD
  11. Stocks Gain As Oil, Euro Continue Sharp Sell Off

    Benzinga
  12. Lands' End Jumps On Strong Quarterly Earnings; GT Advanced Technologies ...

    Benzinga
  13. U.S. Stocks Rise; Palo Alto Networks Shares Surge On Upbeat Revenue

    Benzinga
  14. Markets Edge Lower; Krispy Kreme Doughnuts Profit Misses Estimates

    Benzinga
  15. Benzinga's Volume Movers

    Benzinga
  16. Morning Market Movers

    Benzinga
  17. FDA Posts Briefing Materials For Advisory Committee Meeting ...

    Benzinga
  18. NPS Pharma Initiates Phase 2a Study Of NPSP795 In Adult Patients ...

    Benzinga
  19. Valeant Goes For Allergan; Analyst Touts Shire Option

    IBD
  20. Mid-Afternoon Market Update: Markets Turn Back As SolarCity Hangs ...

    Benzinga
  21. Mid-Day Market Update: Keurig Green Mountain Jumps On Upbeat ...

    Benzinga
  22. Mid-Morning Market Update: Markets Gain; Wendy's Profit Beats ...

    Benzinga
  23. Morning Market Losers

    Benzinga
  24. UPDATE: Canaccord Genuity Assumes Coverage on NPS Pharmaceuticals ...

    Benzinga
  25. Benzinga's Top Initiations

    Benzinga
  26. UPDATE: Jefferies Downgrades NPS Pharmaceuticals on Valuation

    Benzinga
  27. NPS Pharma Finds Big Success In Tiny Markets

    IBD
  28. Market Wrap For January 8: Fed Minutes Released

    Benzinga
  29. NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara ...

    Benzinga
  30. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts
  31. Mid-Afternoon Market Update: Markets Mixed as Tesla Shares Remain ...

    Benzinga
  32. NPS Pharma Says Data from STEPS 2 Trial of Gattex Supports Long-Term ...

    Benzinga
  33. Mid-Afternoon Market Update: Markets Green as Spirit Airlines ...

    Benzinga
  34. Mid-Day Market Update: Micron Shares Tumble On Downbeat Profit; ...

    Benzinga
  35. Mid-Morning Market Update: Markets Rise; JPMorgan Posts Upbeat ...

    Benzinga
  36. Orphan Drugs: No (Payer) News Is Good News

    YCharts
  37. NPS Pharma Says 53% of Natpara-Treated Patients Achieved Primary ...

    Benzinga
  38. UPDATE: Bank of America Initiates Coverage on NPS Pharmaceuticals ...

    Benzinga
  39. Benzinga's Top Initiations

    Benzinga
  40. NPS Pharma Says sNDA Submitted for Gattex STEPS 2 Data, Shows ...

    Benzinga
  41. Weekly CFO Sells Highlight: WRES, NPSP, MKTO, GRPN, RXN

    GuruFocus
  42. UPDATE: J.P. Morgan Initiates Coverage on NPS Pharmaceuticals ...

    Benzinga
  43. Benzinga's Top Initiations

    Benzinga
  44. UPDATE: Oppenheimer Raises PT on NPS Pharmaceuticals Following ...

    Benzinga
  45. Market Wrap for Friday, August 9: Stocks Close Lower To End Week

    Benzinga
  46. NPS Pharmaceuticals Chief: Why 250k-a-Year Orphan Drug is Worth ...

    YCharts
  47. You Can Expect More Insider Trading in Pharma Stocks: Here's ...

    YCharts
  48. FDA Approves NPS Gattex for Injection for Some SBS Patients

    Benzinga
  49. NPS Pharma Shares Moving Lower Amid FDA Approval of Gattex

    Benzinga
  50. NPS Pharma Publishes Pivotal Phase 3 Study of Gattex in Short ...

    Benzinga
  51. NPS Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  52. Benzinga Mid-Afternoon Market Update

    Benzinga
  53. Benzinga Mid-Day Market Update

    Benzinga
  54. Benzinga Mid-Morning Market Update

    Benzinga
  55. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT ...

    Benzinga
  56. FDA Advisory Committee Unanimously Recommends Approval of Gattex® ...

    Benzinga
  57. Benzinga Mid-Day Market Update

    Benzinga
  58. Benzinga Mid-Afternoon Market Update

    Benzinga
  59. Benzinga Mid-Morning Market Update

    Benzinga
  60. UPDATE: Morgan Stanley Initiates NPS Pharmaceuticals at Overweight ...

    Benzinga
  61. Benzinga's Top Pre-Market Gainers

    Benzinga
  62. NPS Pharma Expects to File Natpara BLA in Mid 2013

    Benzinga
  63. Revestive Receives European Marketing Authorization for the Treatment ...

    Benzinga
  64. NPS Pharma Says Gattex Meeting October 16th

    Benzinga
  65. Biotechs With Upcoming PDUFA Dates

    Benzinga
  66. NPS Pharmaceuticals (NPSP) Gains 10.8% as Short Bowel Drug Moves ...

    MarketIntelligenceCenter
  67. Social Media Outlook for Friday June 22 (DRI, NPSP, R, GS)

    Benzinga
  68. Benzinga's Top Pre-Market Gainers

    Benzinga
  69. NPS Pharmaceuticals Reports NatparaTM Phase 3 Results to be Presented ...

    Benzinga
  70. NPS Pharmaceuticals Inc. Reports Operating Results (10-K)

    GuruFocus
  71. Benzinga's Top Pre-Market Gainers

    Benzinga
  72. Notable Call Options Activity in NPS Pharmaceuticals

    Benzinga
  73. Put Volume Surges on Plunging NPS Pharmaceuticals

    SchaeffersResearch
Trading Center